tbuckley/cabot-search huggingface dataset:
Prognostic significance of fascin overexpression in rectal cancer
Authors: M. S. Roh, J. H. Lee, H. Kwon, K. J. Park, H. J. Choi, S. Cho
Journal: Journal of Clinical Oncology (2006)

13517 Background: Fascin is an actin-bundling protein that induces cell membrane protrusions and increases motility of normal and various transformed epithelial cells. In normal epithelial cells, fascin expression is usually absent or very low, but is often upregulated in several types of human neoplasms. However, the clinicopathological features of fascin expression in rectal cancer are still unknown. Methods: Immunohistochemistry for fascin was performed in 79 rectal cancers. Staining more than 5% of tumor cells was recorded as positive immunoreactivity. Results: Overall, fascin immunoreactivity was detected in 63 (79.7%) out of a total 79 cases. Increased immunoreactivity of fascin was sometimes seen at the invading edge of the tumor. Fascin expression was correlated with TNM staging (p=0.001), positive lymph node metastasis (p=0.001), tumor budding (p=0.001), lymphovascular invasion (p=0.001) and perineural invasion (p=0.039); however, recurrence was not statistically significant (p=0.068). Overall survival rate of patients with fascin-positive tumors was significantly lower than that of patients with fascin-negative tumors (p=0.012). Conclusions: Therefore, we suggest that the overexpression of fascin in rectal cancer may be implicated not only in tumor growth but also in the development of metastases. Our findings indicate that the immunohistochemical detection of fascin could provide useful information as one of the prognostic factor in rectal cancer. No significant financial relationships to disclose.
A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful p
Authors: L. Eibenschutz, V. Silipo, P. De Simone, P.L. Buccini, A. Ferrari, A. Carbone, C. Catricalà
Journal: British Journal of Dermatology (2016)
GW26-e4650 Prenatal diagnosis of Ebstein’s anomaly by fetal echocardiography and additional information provided by spatiotemporal image correlation with tomographic ultrasound imaging (STIC-TUI)
Authors: Haiyan Cao, Wei Han, Yu Wang, Liu Hong, Yunfei Hu, Mingxing Xie
Journal: Journal of the American College of Cardiology (2015)
GW26-e5418 Revascularization of TASC C/D Iliac Occlusion Extended to Common/Superficial Femoral Artery Using a Mixed Endoluminal and Subintimal Technique through the Radio-Brachial Access
Authors: Gianluca Rigatelli, Dobrin Vassiliev, Fabio dell' Avvocata, Alberto Rigatelli, Massimo Giordan, Phillip Tran, Vo Minh Viet
Journal: Journal of the American College of Cardiology (2015)
Experience with Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Study of 56 Patients in a Single Institute of China
Authors: Xiao Shuai, Ting Liu, Ting Niu, Hong Chang, Jianjun Li, Jie Huang, Xu Cui, Jie Ji, Hongbing Ma, Bing Xiang, Chuan He, Yu Wu, Yuping Gong
Journal: Blood (2011)
Persistent pulmonary hypertension and right ventricular function after percutaneous mechanical thrombectomy in severe acute pulmonary embolism
Authors: Guering Eid-Lidt, Jorge Gaspar, Julio Sandoval, Hector Gonzalez-Pacheco, Antonio Arias, Pablo Acevedo, Tomas Pulido, Carlos Martinez-Sanchez, Marco Antonio Martinez-Rios
Journal: European Respiratory Journal (2016)

Acute pulmonary embolism is one of the main causes of death, morbidity and hospitalisation [1, 2]. The most common cause of early death in these patients is right ventricular failure [1–3]. Complete resolution of the pulmonary thrombus at 6 months of evolution is not achieved in 57% of patients, with persistent right ventricular dysfunction (RVD) in 6–8% of patients and persistent pulmonary arterial hypertension (PAH) in 7–13.5% of patients who received treatment with heparin or fibrinolytic agents [4–8]. Percutaneous mechanical thrombectomy (PMT) is accepted as a treatment in patients with high-risk acute pulmonary embolism with contraindications to systemic thrombolysis or when the treatment has failed [1, 2, 9]. Percutaneous mechanical thrombectomy in acute PE restores right ventricle function in most patients at 40 months <http://ow.ly/lhTh304sqeY>
FOXK2 Elicits Massive Transcription Repression and Suppresses the Hypoxic Response and Breast Cancer Carcinogenesis
Authors: Lin Shan, Xing Zhou, Xinhua Liu, Yue Wang, Dongxue Su, Yongqiang Hou, Na Yu, Chao Yang, Beibei Liu, Jie Gao, Yang Duan, Jianguo Yang, Wanjin Li, Jing Liang, Luyang Sun, Kexin Chen, Chenghao Xuan, Lei Shi, Yan Wang, Yongfeng Shang
Journal: Cancer Cell (2016)
Improved Survival in Acute Myeloid Leukaemia Patients Aged over 40 Given Cladribine in Combination with Standard Remission Induction (DA 3+7) and Consolidation Treatment (HD AraC). Seven Year Follow-Up of Prospective, Cooperative PALG Study.
Authors: Jerzy Holowiecki, Sebastian Grosicki, Andrzej Hellmann, Aleksander Skotnicki, Tadeusz Robak, Wieslaw W. Jedrzejczak, Lech Konopka, Kazimierz Kuliczkowski, Slawomira Kyrcz-Krzemien, Beata Stella-Holowiecka
Journal: Blood (2006)
GW26-e0809 The Relationship between Urokinase-type Plasminogen Activator and Its Receptor and the Stenosis of the Coronary Artery in Patients with Coronary Heart Disease
Authors: Zhenda Zheng, Cailian Cheng, Lin Wu, Dinghui Liu, Zhiming Song, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2015)
Risk Factors for Mortality In Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.
Authors: Fátima de la Cruz Vicente, Omar BenMarzouk-Hidalgo, Irene Gracia-Ahufinger, Raul García-Lozano, Manuela Aguilar-Guisado, Jose Miguel Cisneros-Herreros, Alvaro Urbano-Ispizua, Pilar Perez-Romero, Ildefonso Espigado
Journal: Blood (2010)
Unfinished Business in Preventing Alzheimer Disease
Authors: Jason Karlawish, Kenneth M. Langa
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Samantha J Mayo, Hans A. Messner, Sean B. Rourke, Doris Howell, J. Charles Victor, John Kuruvilla, Jeffrey H. Lipton, Vikas Gupta, Dennis Dong Hwan Kim, Laura McGillis, Jieun Uhm, Fotios V. Michelis, Naheed Alam, Anna Lambie, Dawn Breen, David Loach, Christine Piescic, Kelly Metcalfe
Journal: Blood (2015)
High Frequency CD4+CD25+ Treg Cells in Nasopharyngeal Carcinoma Is Associated with Suppression of CD8 T Cell Mediated Response to Latency II EBV Antigens.
Authors: Frederick E. Chen, Wensheng Wen, Guangwu Huang, Paul Travers, I. Anthony Dodi, J. Alejandro Madrigal
Journal: Blood (2004)
GW26-e2433 Prevalence of Liddle syndrome among young hypertension patients of undetermined cause in a Chinese population
Authors: Kunqi Yang, Linping Wang, Xiongjing Jiang, Haiying Wu, Huimin Zhang, Yubao Zou, Lei Song, Jin Bian, Rutai Hui, Yaxin Liu, Xianliang Zhou
Journal: Journal of the American College of Cardiology (2015)
GW26-e4504 Sympathetic Nerve Remodeling in Hypertensive Rabbits with Left Ventricular Hypertrophy and Heart Failure
Authors: Kangyin Chen, Tigang Huang, None Tongliu, Yongjian Li, Xin Zhou, Wei Cai, Guangping Li, Yuming Li
Journal: Journal of the American College of Cardiology (2015)
Plasma Coenzyme Q10 Levels and Multiple System Atrophy—Reply
Authors: Jun Mitsui, Shoji Tsuji
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Induction of Chronic Lymphocytic Leukemia (CLL) Apoptosis by Nitric Oxide Synthase (NOS) Inhibitors: Drug Efficacy Correlates with Lipid Solubility and NOS1 Dissociation Constant.
Authors: Marc C. Levesque, Dipak K. Ghosh, Bethany E. Beasley, Youwei Chen, Alicia D. Volkheimer, Charles W. O’Loughlin, Jon P. Gockerman, Joseph O. Moore, J. Brice Weinberg
Journal: Blood (2005)
Improved Outcome of Acute Leukemia Patients Followed up In out-Patient Setting After High Dose Ara-C (HDAC) Consolidation with Infection Prophylaxis Strategies
Authors: Omyma El-Emam, Syed Ziauddin A. Zaidi, Bassim Albeirouti, Abdul-Aziz Al-Humaidi, Ali Al-Shanqeeti
Journal: Blood (2010)
Stage at breast cancer diagnosis is more advanced in BRCA1 carriers but not in BRCA2 carriers
Authors: B. Kaufman, A. Lahad, M. Krieger, M. Gal, E. Friedman, P. Renbaum, A. Gabizon, S. Paluch-Shimon, R. Catane, E. Levy-Lahad
Journal: Journal of Clinical Oncology (2007)

10540 Background: BRCA1-associated tumors are known to have less favorable pathological characteristics, but there is little information on whether this is also reflected in the stage at diagnosis. Methods: Clinical and pathological information was collected on 1,122 consecutive Ashkenazi Jewish breast cancer patients who were tested post-diagnosis for the BRCA1/2 mutations common in this population. Results: Of 1,122 patients, 70 (6.2%) were BRCA1 and 50 (4.5%) were BRCA2 carriers. Mean age at diagnosis was 49.9 yrs. in BRCA1 carriers (p=.0001 vs. non-carriers (NC)) vs. 52.0 yrs. in BRCA2 carriers (p=.02 vs. NC) and 56.0 yrs. in NC. Pure DCIS was less common in BRCA1 carriers (3%) than in BRCA2 carriers (8.2%) and NC (11.8%) (p=.03). Medullary carcinoma was more common in BRCA1 (9.8%) and BRCA2 carriers (6.7%) than in NC (1.5%) (p&lt;.001). Invasive lobular carcinomas were rarer in BRCA1 (1.6%) and BRCA2 (2.2%) compared to NC (8.8%) (p=.012). Hormone receptors (HR) negative was more common in BRCA1 (62%) compared to BRCA2 carriers (21%) (p=.00006) and NC (17%) (p&lt;0.0001). Triple negative tumors (HR and HER2 negative) were more common in BRCA1 carriers (60%) than in BRCA2 carriers (14%) and NC (8.3%) (p=0.001). High grade was more common in BRCA1 (60.4%) and BRCA2 (51.4%) carriers than in NC (36.7%, p=.001). Less favorable pathological features and younger age at diagnosis in BRCA1 carriers were reflected in a more advanced stage at diagnosis. Stage I at diagnosis was found in 34% of BRCA1 carriers (p=.05 vs. NC), 43% of BRCA2 carriers and 46% of NC, stage II in 48% of BRCA1 carriers, 41% of BRCA2 carriers and 37% of NC, and stage III in 17% of BRCA1 carriers, 13.5% of BRCA2 carriers and 13.5% of non-carriers. Conclusions: This consecutive cohort study demonstrates that breast cancers in BRCA1 carriers are characterized by more aggressive pathological features and are diagnosed at more advanced stages than in BRCA2 carriers and non-carriers. This may suggest a differential approach for prevention and surveillance in BRCA1 compared to BRCA2 carriers. No significant financial relationships to disclose.
Outcomes of Endovascular Repair of Ascending Aortic Dissection in Patients Unsuitable for Direct Surgical Repair
Authors: Zhenjiang Li, Qingsheng Lu, Rui Feng, Jian Zhou, Zhiqing Zhao, Junmin Bao, Xiang Feng, Jiaxuan Feng, Yifei Pei, Chao Song, Zaiping Jing
Journal: Journal of the American College of Cardiology (2016)
Safety of neoadjuvant oxaliplatin-based chemotherapy (N-FOLFOX) in patients undergoing resection of colorectal liver metastases (R-CLM). Interim results
Authors: M. Verghese, S. Pathak, C. Foster, M. Haqqani, G. J. Poston
Journal: Journal of Clinical Oncology (2007)

14550 Background: Oxaliplatin-5-fluorouracil-leucovorin (FOLFOX) has significant activity against CRC in both the metastatic and adjuvant settings. Consequently, neoadjuvant FOLFOX (N-FOLFOX) is being investigated in R-CLM. This has raised concerns regarding the safety and rate of post-operative complications (P-OCs) with N-FOLFOX, specifically, development of sinusoidal dilatation (SD), fibrosis and steatosis. This single-center cohort study was conducted to prospectively evaluate safety of N-FOLFOX in R-CLM patients. Methods: Planned total sample size is 40 patients [20 N-FOLFOX; 20 no chemotherapy (N-C)]. The N-C group consists of patients undergoing surgery for other hepatic pathology. Normal liver was examined by light (LM) and electron (EM) microscopy for SD, perisinusoidal fibrosis, and steatosis/necrosis; severity was graded from 0 (absent) to 2. The rate of P-OCs, hospital stays, and liver function tests (LFTs) were assessed. Results: At the time of this analysis, 20 patients (10 N-FOLFOX; 10 N-C) have undergone surgery. In the N- FOLFOX group, median number of cycles of N-FOLFOX was 6, with 2 patients receiving only 4 cycles. The median time between completion of N-FOLFOX and surgery was 6 weeks. There were no statistical differences between N-FOLFOX and N-C groups in potentially confounding factors, including previous chemotherapy, alcohol consumption, medical history, or concomitant medications. Number of patients with SD was 8 in each group (all were grade 1 except for 1 patient in N-C who had grade 2). Steatosis was seen in 7 and 6 patients in N-FOLFOX, and N-C groups, respectively (2 patients in each group were grade 2; remaining were grade 1). Fibrosis was noted in only 1 patient in N-C group. No nodular regeneration was observed in either group. There was a subjective loss on EM of mitochondria and Golgi apparatus/body with N-FOLFOX. Median post-operative hospital stay was 12 days in both groups. Conclusions: N-FOLFOX appears to have no clinically significant deleterious effects on normal liver architecture, function, or recovery post-surgery in R-CLM patients. The study is ongoing to accrue up to 40 patients; updated data will be presented. No significant financial relationships to disclose.
Topotecan and etoposide as salvage chemotherapy in patients with irinotecan- and platinum-failed small-cell lung cancer: A phase II study
Authors: H. Choi, B. Choi, S. Shin, S. Cheon, S. Cheon, J. Jung, Y. Kim, J. Sohn, J. Kim, J. Kim
Journal: Journal of Clinical Oncology (2007)

18177 Background: The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. Methods: From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan 1mg/m 2 (day 1–5) followed by intravenous etoposide 80mg/m 2 (day 1–3). Treatment was repeated every 21 days for a maximum of 6 cycles. Results: Twelve patients were refractory to first-line chemotherapy. Seventeen patients (73.9%) were male and the median age was 63 years. ECOG performance status was 0–1 in 13 (56.5%) patients. The median cycles of chemotherapy was 3. Twenty one patients were assessable for response evaluation. The overall response rate was 17.4% (0 CR, 4 PR, 7 SD, 10 PD) under the intent-to-treat analysis. After a median follow- up of 20.8 months, median progression free survival was 4.7 months and median overall survival was 9.5 months. The estimated 1-year survival rate was 38.7%. In sensitive relapsed patients, 2 achieved tumor response and median progression free survival and overall survival were 5.5 months and 14.5 months. All patients were assessable for toxicity and major toxicities were myelosuppression. Grade 3/4 neutropenia and thrombocytopenia occurred in 18 (78.3%) and 12 (52.2%) patients, respectively. Grade 3/4 febrile neutropenia occurred in 2 patients (8.7 %) and infection in 3 patients (13.0%). There was one treatment-related death due to pneumonia. Conclusions: This salvage regimen failed to demonstrate a considerable response rate compared with monotherapy for relapsed or refractory SCLC. However, the combination of topotecan and etoposide could be further studied for sensitive relapsed patients pretreated with irinotecan and platinum No significant financial relationships to disclose.
Trends in the Incidence of Parkinson Disease—Reply
Authors: Walter A. Rocca, Rodolfo Savica, Brandon R. Grossardt
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
GW26-e4663 The gender difference in short and long-term outcomes for coronary rotational atherectomy, a single-center retrospective analysis
Authors: Lei Song, Yin Zhang, Jinqing Yuan, Yuejin Yang, Shubin Qiao, Yongjian Wu, Hongbing Yan, Kefei Dou, Bo Xu, Jilin Chen, Runlin Gao, Jue Chen
Journal: Journal of the American College of Cardiology (2015)
Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project
Authors: B. E. Chatterton, I. Ho-Shon, N. Lenzo, A. Patrikeos, B. Kelley, A. Baldey, J. Ramshaw, A. Scott
Journal: Journal of Clinical Oncology (2007)

4534 Background: In localized EC, radical surgery may be curative. This study evaluated PET and conventional imaging techniques (CI) for staging, and the potential impact of PET on management and prognosis of EC. Methods: Subjects had confirmed EC (SCC or adenocarcinoma), were fit for investigation and surgery and/or chemoradiotherapy and had no unequivocal distant metastatic disease clinically or by CT and endoscopy at presentation. Sensitivity, including N and M staging of pre-operative CT, PET and endoscopic ultrasound (EUS) and clinical impact of confirmation or detection of metastases on intent (curative or palliative) were recorded. Management changes, including radiotherapy field determined by new information from PET, were recorded. Variables, including standardized uptake value (SUV) were compared with progression-free survival (PFS.) Results: 129 patients (104 male), mean age 66 (range 36- 87) were evaluated. 127 of 129 primary lesions were detected. In 41% of patients, PET detected a total of 148 additional lesions, 75 regional lymph nodes, 72 distant metastases and 1 second EC primary. 22% of patients were upstaged from M0 to M1. CT detected regional and distant metastases in 57% and 0% (entry criterion), PET in 70% and 44%. Of 20 patients who had EUS, it detected regional metastases in 67%, PET in 33%.The number of patients intended to be treated palliatively increased from 10 pre- to 32 post-PET. Of patients with curative management intent based on PET 34% progressed in 12 months, with palliative intent 59%. Significant changes in management (high or medium impact) occurred in 38%. The PFS of 54 patients below and 54 above the median SUV(8) was no different (p=0.79) Conclusions: PET influenced management in 38% of patients with EC already studied by CI. No significant financial relationships to disclose.
Big Data–Led Cancer Research, Application, and Insights
Authors: James A.L. Brown, Triona Ni Chonghaile, Kyle B. Matchett, Niamh Lynam-Lennon, Patrick A. Kiely
Journal: Cancer Research (2016)

Insights distilled from integrating multiple big-data or "omic" datasets have revealed functional hierarchies of molecular networks driving tumorigenesis and modifiers of treatment response. Identifying these novel key regulatory and dysregulated elements is now informing personalized medicine. Crucially, although there are many advantages to this approach, there are several key considerations to address. Here, we examine how this big data-led approach is impacting many diverse areas of cancer research, through review of the key presentations given at the Irish Association for Cancer Research Meeting and importantly how the results may be applied to positively affect patient outcomes. Cancer Res; 76(21); 6167-70. ©2016 AACR.